Recent Trends and Innovations in the Management of CLL

ASH 2025 reveals groundbreaking trial data on fixed-duration therapies for chronic lymphocytic leukemia, non-Hodgkin lymphoma, and multiple myeloma, enhancing patient outcomes and reducing costs.

Lead CML researcher discusses the evolution of a groundbreaking treatment and its effect on patient survival.

Sequential BTK and BCL2 inhibitors yield high initial response rates, but durability remains a challenge in the real-world setting for CLL.

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

With a follow-up of up to 6 years, the median progression-free survival for long-term extension participants was 52.5 months.

The study suggests that adding a Bruton tyrosine kinase inhibitor (BTKi) to frontline chemoimmunotherapy in Richter transformation improved complete response rates and progression-free survival compared with chemoimmunotherapy alone, though overall survival benefits remained unclear.